TY  - JOUR
A1  - Kim, HoUng
A1  - Alten, Rieke
A1  - Avedano, Luisa
A1  - Dignass, Axel Uwe
A1  - Gomollón, Fernando
A1  - Greveson, Kay
A1  - Halfvarson, Jonas
A1  - Irving, Peter M.
A1  - Jahnsen, Jørgen
A1  - Lakatos, Peter Laszlo
A1  - Lee, JongHyuk
A1  - Makri, Souzi
A1  - Parker, Ben
A1  - Peyrin‑Biroulet, Laurent
A1  - Schreiber, Stefan
A1  - Simoens, Steven
A1  - Westhovens, Rene
A1  - Danese, Silvio
A1  - Jeong, Ji Hoon
T1  - The future of biosimilars: Maximizing benefits across immune-mediated inflammatory diseases
T2  - Drugs
N2  - Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators—can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53074
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-530745
SN  - 1179-1950
SN  - 0012-6667
N1  - Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
IS  - 2
SP  - 99
EP  - 113
PB  - Springer
CY  - Berlin [u. a.]
ER  -